nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—EDNRA—EGFR-dependent Endothelin signaling events—EGFR—head and neck cancer	0.00923	0.0354	CbGpPWpGaD
Sitaxentan—EDNRA—EGFR-dependent Endothelin signaling events—HRAS—head and neck cancer	0.00741	0.0284	CbGpPWpGaD
Sitaxentan—Pericardial effusion—Docetaxel—head and neck cancer	0.00717	0.00969	CcSEcCtD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—head and neck cancer	0.00694	0.0266	CbGpPWpGaD
Sitaxentan—Skin hyperpigmentation—Fluorouracil—head and neck cancer	0.00685	0.00926	CcSEcCtD
Sitaxentan—Cellulitis—Vinblastine—head and neck cancer	0.00682	0.00923	CcSEcCtD
Sitaxentan—Dysaesthesia—Docetaxel—head and neck cancer	0.0068	0.0092	CcSEcCtD
Sitaxentan—EDNRB—G alpha (q) signalling events—KISS1—head and neck cancer	0.00678	0.026	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.0067	0.0257	CbGpPWpGaD
Sitaxentan—Ascites—Docetaxel—head and neck cancer	0.00647	0.00875	CcSEcCtD
Sitaxentan—Amenorrhoea—Hydroxyurea—head and neck cancer	0.00644	0.00871	CcSEcCtD
Sitaxentan—Raised liver function tests—Docetaxel—head and neck cancer	0.00637	0.00861	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.00607	0.0233	CbGpPWpGaD
Sitaxentan—Hepatic enzyme increased—Hydroxyurea—head and neck cancer	0.00598	0.00809	CcSEcCtD
Sitaxentan—Photophobia—Vinblastine—head and neck cancer	0.00583	0.00788	CcSEcCtD
Sitaxentan—Blood uric acid increased—Hydroxyurea—head and neck cancer	0.00576	0.0078	CcSEcCtD
Sitaxentan—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.00568	0.0218	CbGpPWpGaD
Sitaxentan—Neoplasm—Vinblastine—head and neck cancer	0.00561	0.00759	CcSEcCtD
Sitaxentan—EDNRB—G alpha (q) signalling events—GRP—head and neck cancer	0.00559	0.0214	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—GRP—head and neck cancer	0.00552	0.0212	CbGpPWpGaD
Sitaxentan—Skin exfoliation—Hydroxyurea—head and neck cancer	0.0054	0.00731	CcSEcCtD
Sitaxentan—Systemic lupus erythematosus—Docetaxel—head and neck cancer	0.00531	0.00718	CcSEcCtD
Sitaxentan—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.00518	0.0198	CbGpPWpGaD
Sitaxentan—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.00517	0.0198	CbGpPWpGaD
Sitaxentan—Neoplasm—Hydroxyurea—head and neck cancer	0.00512	0.00692	CcSEcCtD
Sitaxentan—Deafness—Vinblastine—head and neck cancer	0.00504	0.00681	CcSEcCtD
Sitaxentan—Haemorrhoids—Docetaxel—head and neck cancer	0.005	0.00676	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.005	0.0192	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—head and neck cancer	0.00497	0.0191	CbGpPWpGaD
Sitaxentan—Skin hyperpigmentation—Docetaxel—head and neck cancer	0.00494	0.00669	CcSEcCtD
Sitaxentan—EDNRA—G alpha (q) signalling events—KISS1—head and neck cancer	0.00486	0.0186	CbGpPWpGaD
Sitaxentan—Polyp—Docetaxel—head and neck cancer	0.00483	0.00654	CcSEcCtD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.00479	0.0184	CbGpPWpGaD
Sitaxentan—Eye irritation—Fluorouracil—head and neck cancer	0.00477	0.00645	CcSEcCtD
Sitaxentan—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.00471	0.0181	CbGpPWpGaD
Sitaxentan—Oral candidiasis—Docetaxel—head and neck cancer	0.00463	0.00626	CcSEcCtD
Sitaxentan—Hepatic failure—Hydroxyurea—head and neck cancer	0.00457	0.00618	CcSEcCtD
Sitaxentan—EDNRB—Endothelin Pathways—MAPK1—head and neck cancer	0.00456	0.0175	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00449	0.0172	CbGpPWpGaD
Sitaxentan—Supraventricular tachycardia—Docetaxel—head and neck cancer	0.00449	0.00607	CcSEcCtD
Sitaxentan—Cellulitis—Fluorouracil—head and neck cancer	0.00448	0.00606	CcSEcCtD
Sitaxentan—Herpes simplex—Fluorouracil—head and neck cancer	0.00442	0.00598	CcSEcCtD
Sitaxentan—Lacrimation increased—Fluorouracil—head and neck cancer	0.00442	0.00598	CcSEcCtD
Sitaxentan—Cyst—Docetaxel—head and neck cancer	0.0044	0.00595	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.00434	0.0167	CbGpPWpGaD
Sitaxentan—Haemoglobin decreased—Docetaxel—head and neck cancer	0.00427	0.00578	CcSEcCtD
Sitaxentan—Inflammation—Fluorouracil—head and neck cancer	0.0042	0.00568	CcSEcCtD
Sitaxentan—Dermatitis contact—Fluorouracil—head and neck cancer	0.00403	0.00545	CcSEcCtD
Sitaxentan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.00401	0.0154	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—GRP—head and neck cancer	0.004	0.0153	CbGpPWpGaD
Sitaxentan—Dermatitis atopic—Docetaxel—head and neck cancer	0.00397	0.00537	CcSEcCtD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—GRP—head and neck cancer	0.00395	0.0151	CbGpPWpGaD
Sitaxentan—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.00385	0.00521	CcSEcCtD
Sitaxentan—Pleural effusion—Docetaxel—head and neck cancer	0.00384	0.00519	CcSEcCtD
Sitaxentan—Photophobia—Fluorouracil—head and neck cancer	0.00382	0.00517	CcSEcCtD
Sitaxentan—Angina pectoris—Vinblastine—head and neck cancer	0.00379	0.00513	CcSEcCtD
Sitaxentan—Otitis media—Docetaxel—head and neck cancer	0.00378	0.00511	CcSEcCtD
Sitaxentan—Breast disorder—Hydroxyurea—head and neck cancer	0.00371	0.00502	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.0037	0.0142	CbGpPWpGaD
Sitaxentan—Pancytopenia—Vinblastine—head and neck cancer	0.0037	0.005	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.00358	0.0137	CbGpPWpGaD
Sitaxentan—Eye irritation—Docetaxel—head and neck cancer	0.00344	0.00466	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00342	0.00463	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—KISS1—head and neck cancer	0.00342	0.0131	CbGpPWpGaD
Sitaxentan—Myocardial infarction—Vinblastine—head and neck cancer	0.0034	0.0046	CcSEcCtD
Sitaxentan—Pancytopenia—Hydroxyurea—head and neck cancer	0.00337	0.00456	CcSEcCtD
Sitaxentan—Amenorrhoea—Docetaxel—head and neck cancer	0.00335	0.00453	CcSEcCtD
Sitaxentan—Chest discomfort—Docetaxel—head and neck cancer	0.00332	0.0045	CcSEcCtD
Sitaxentan—Dysuria—Hydroxyurea—head and neck cancer	0.00332	0.00449	CcSEcCtD
Sitaxentan—EDNRA—Endothelin Pathways—MAPK1—head and neck cancer	0.00326	0.0125	CbGpPWpGaD
Sitaxentan—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.00323	0.00437	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00322	0.0123	CbGpPWpGaD
Sitaxentan—Lacrimation increased—Docetaxel—head and neck cancer	0.00319	0.00432	CcSEcCtD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00318	0.0122	CbGpPWpGaD
Sitaxentan—Infestation NOS—Hydroxyurea—head and neck cancer	0.00317	0.00428	CcSEcCtD
Sitaxentan—Infestation—Hydroxyurea—head and neck cancer	0.00317	0.00428	CcSEcCtD
Sitaxentan—Haemoglobin—Vinblastine—head and neck cancer	0.00313	0.00424	CcSEcCtD
Sitaxentan—Haemorrhage—Vinblastine—head and neck cancer	0.00312	0.00422	CcSEcCtD
Sitaxentan—Blood bilirubin increased—Docetaxel—head and neck cancer	0.00311	0.00421	CcSEcCtD
Sitaxentan—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.00311	0.0119	CbGpPWpGaD
Sitaxentan—Stomatitis—Hydroxyurea—head and neck cancer	0.00309	0.00417	CcSEcCtD
Sitaxentan—Inflammation—Docetaxel—head and neck cancer	0.00303	0.0041	CcSEcCtD
Sitaxentan—Cardiac failure—Fluorouracil—head and neck cancer	0.00303	0.0041	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00299	0.00405	CcSEcCtD
Sitaxentan—Respiratory failure—Docetaxel—head and neck cancer	0.00299	0.00405	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00296	0.004	CcSEcCtD
Sitaxentan—Osteoarthritis—Fluorouracil—head and neck cancer	0.00296	0.004	CcSEcCtD
Sitaxentan—Blood pressure increased—Docetaxel—head and neck cancer	0.00294	0.00398	CcSEcCtD
Sitaxentan—Pulmonary embolism—Docetaxel—head and neck cancer	0.00294	0.00398	CcSEcCtD
Sitaxentan—EDNRB—Endothelins—MAPK3—head and neck cancer	0.00286	0.011	CbGpPWpGaD
Sitaxentan—Haemoglobin—Hydroxyurea—head and neck cancer	0.00286	0.00386	CcSEcCtD
Sitaxentan—Haemorrhage—Hydroxyurea—head and neck cancer	0.00284	0.00384	CcSEcCtD
Sitaxentan—Colitis—Docetaxel—head and neck cancer	0.00282	0.00382	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—GRP—head and neck cancer	0.00282	0.0108	CbGpPWpGaD
Sitaxentan—Candida infection—Docetaxel—head and neck cancer	0.00281	0.0038	CcSEcCtD
Sitaxentan—Skin exfoliation—Docetaxel—head and neck cancer	0.00281	0.0038	CcSEcCtD
Sitaxentan—Fluid retention—Docetaxel—head and neck cancer	0.00279	0.00378	CcSEcCtD
Sitaxentan—Ataxia—Fluorouracil—head and neck cancer	0.00278	0.00376	CcSEcCtD
Sitaxentan—Alopecia—Vinblastine—head and neck cancer	0.00275	0.00373	CcSEcCtD
Sitaxentan—CYP2C19—Xenobiotics—CYP1A1—head and neck cancer	0.00273	0.0105	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—MAPK1—head and neck cancer	0.00272	0.0104	CbGpPWpGaD
Sitaxentan—Dry skin—Fluorouracil—head and neck cancer	0.00271	0.00367	CcSEcCtD
Sitaxentan—Neoplasm—Docetaxel—head and neck cancer	0.00266	0.0036	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00265	0.0102	CbGpPWpGaD
Sitaxentan—CYP2C19—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.00262	0.0101	CbGpPWpGaD
Sitaxentan—Muscular weakness—Fluorouracil—head and neck cancer	0.00261	0.00353	CcSEcCtD
Sitaxentan—Angiopathy—Hydroxyurea—head and neck cancer	0.00258	0.00349	CcSEcCtD
Sitaxentan—Eosinophilia—Fluorouracil—head and neck cancer	0.00253	0.00342	CcSEcCtD
Sitaxentan—Ill-defined disorder—Vinblastine—head and neck cancer	0.00252	0.00341	CcSEcCtD
Sitaxentan—Alopecia—Hydroxyurea—head and neck cancer	0.00251	0.0034	CcSEcCtD
Sitaxentan—Anaemia—Vinblastine—head and neck cancer	0.00251	0.00339	CcSEcCtD
Sitaxentan—Angina pectoris—Fluorouracil—head and neck cancer	0.00249	0.00337	CcSEcCtD
Sitaxentan—CYP2C9—Xenobiotics—CYP1A1—head and neck cancer	0.00249	0.00954	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—KISS1—head and neck cancer	0.00245	0.00939	CbGpPWpGaD
Sitaxentan—Malaise—Vinblastine—head and neck cancer	0.00245	0.00331	CcSEcCtD
Sitaxentan—Vertigo—Vinblastine—head and neck cancer	0.00244	0.0033	CcSEcCtD
Sitaxentan—Leukopenia—Vinblastine—head and neck cancer	0.00243	0.00328	CcSEcCtD
Sitaxentan—Pancytopenia—Fluorouracil—head and neck cancer	0.00243	0.00328	CcSEcCtD
Sitaxentan—CYP2C9—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.00239	0.00917	CbGpPWpGaD
Sitaxentan—Deafness—Docetaxel—head and neck cancer	0.00239	0.00323	CcSEcCtD
Sitaxentan—Hepatic failure—Docetaxel—head and neck cancer	0.00237	0.00321	CcSEcCtD
Sitaxentan—Cardiac failure congestive—Docetaxel—head and neck cancer	0.00235	0.00318	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00233	0.00316	CcSEcCtD
Sitaxentan—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.0023	0.00311	CcSEcCtD
Sitaxentan—Anaemia—Hydroxyurea—head and neck cancer	0.00229	0.00309	CcSEcCtD
Sitaxentan—Discomfort—Vinblastine—head and neck cancer	0.00228	0.00309	CcSEcCtD
Sitaxentan—Infestation NOS—Fluorouracil—head and neck cancer	0.00228	0.00308	CcSEcCtD
Sitaxentan—Infestation—Fluorouracil—head and neck cancer	0.00228	0.00308	CcSEcCtD
Sitaxentan—Menopausal symptoms—Docetaxel—head and neck cancer	0.00226	0.00306	CcSEcCtD
Sitaxentan—Visual disturbance—Docetaxel—head and neck cancer	0.00225	0.00305	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00225	0.00304	CcSEcCtD
Sitaxentan—Renal impairment—Docetaxel—head and neck cancer	0.00224	0.00303	CcSEcCtD
Sitaxentan—Myocardial infarction—Fluorouracil—head and neck cancer	0.00223	0.00302	CcSEcCtD
Sitaxentan—Malaise—Hydroxyurea—head and neck cancer	0.00223	0.00302	CcSEcCtD
Sitaxentan—Stomatitis—Fluorouracil—head and neck cancer	0.00222	0.003	CcSEcCtD
Sitaxentan—Conjunctivitis—Fluorouracil—head and neck cancer	0.00221	0.003	CcSEcCtD
Sitaxentan—Leukopenia—Hydroxyurea—head and neck cancer	0.00221	0.003	CcSEcCtD
Sitaxentan—Cardiac failure—Docetaxel—head and neck cancer	0.00219	0.00296	CcSEcCtD
Sitaxentan—EDNRB—Endothelins—HRAS—head and neck cancer	0.00218	0.00837	CbGpPWpGaD
Sitaxentan—Thrombocytopenia—Vinblastine—head and neck cancer	0.00217	0.00293	CcSEcCtD
Sitaxentan—Epistaxis—Fluorouracil—head and neck cancer	0.00215	0.00291	CcSEcCtD
Sitaxentan—Sinusitis—Fluorouracil—head and neck cancer	0.00214	0.00289	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00213	0.00289	CcSEcCtD
Sitaxentan—Anorexia—Vinblastine—head and neck cancer	0.00211	0.00285	CcSEcCtD
Sitaxentan—Migraine—Docetaxel—head and neck cancer	0.0021	0.00284	CcSEcCtD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.0021	0.00804	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00209	0.00283	CcSEcCtD
Sitaxentan—Discomfort—Hydroxyurea—head and neck cancer	0.00208	0.00282	CcSEcCtD
Sitaxentan—Haemoglobin—Fluorouracil—head and neck cancer	0.00206	0.00278	CcSEcCtD
Sitaxentan—Rhinitis—Fluorouracil—head and neck cancer	0.00205	0.00277	CcSEcCtD
Sitaxentan—Haemorrhage—Fluorouracil—head and neck cancer	0.00205	0.00277	CcSEcCtD
Sitaxentan—EDNRA—Endothelins—MAPK3—head and neck cancer	0.00205	0.00784	CbGpPWpGaD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.00203	0.00777	CbGpPWpGaD
Sitaxentan—Oedema—Hydroxyurea—head and neck cancer	0.00202	0.00273	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—GRP—head and neck cancer	0.00202	0.00773	CbGpPWpGaD
Sitaxentan—Ataxia—Docetaxel—head and neck cancer	0.00201	0.00271	CcSEcCtD
Sitaxentan—Infection—Hydroxyurea—head and neck cancer	0.00201	0.00271	CcSEcCtD
Sitaxentan—Dehydration—Docetaxel—head and neck cancer	0.00198	0.00269	CcSEcCtD
Sitaxentan—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00198	0.00268	CcSEcCtD
Sitaxentan—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00198	0.00267	CcSEcCtD
Sitaxentan—Liver function test abnormal—Docetaxel—head and neck cancer	0.00197	0.00267	CcSEcCtD
Sitaxentan—Skin disorder—Hydroxyurea—head and neck cancer	0.00196	0.00265	CcSEcCtD
Sitaxentan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.00196	0.00752	CbGpPWpGaD
Sitaxentan—Dry skin—Docetaxel—head and neck cancer	0.00196	0.00265	CcSEcCtD
Sitaxentan—Abdominal pain upper—Docetaxel—head and neck cancer	0.00195	0.00264	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Docetaxel—head and neck cancer	0.00195	0.00264	CcSEcCtD
Sitaxentan—EDNRA—Endothelins—MAPK1—head and neck cancer	0.00195	0.00746	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—KISS1—head and neck cancer	0.00193	0.00741	CbGpPWpGaD
Sitaxentan—Breast disorder—Docetaxel—head and neck cancer	0.00193	0.00261	CcSEcCtD
Sitaxentan—EDNRB—Endothelins—AKT1—head and neck cancer	0.00193	0.00739	CbGpPWpGaD
Sitaxentan—Anorexia—Hydroxyurea—head and neck cancer	0.00192	0.0026	CcSEcCtD
Sitaxentan—Decreased appetite—Vinblastine—head and neck cancer	0.00192	0.0026	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00192	0.0026	CcSEcCtD
Sitaxentan—Cramp muscle—Docetaxel—head and neck cancer	0.00192	0.0026	CcSEcCtD
Sitaxentan—Pain—Vinblastine—head and neck cancer	0.00189	0.00256	CcSEcCtD
Sitaxentan—Constipation—Vinblastine—head and neck cancer	0.00189	0.00256	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00188	0.00255	CcSEcCtD
Sitaxentan—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.00188	0.00722	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Vinblastine—head and neck cancer	0.00182	0.00247	CcSEcCtD
Sitaxentan—Alopecia—Fluorouracil—head and neck cancer	0.00181	0.00245	CcSEcCtD
Sitaxentan—Angina pectoris—Docetaxel—head and neck cancer	0.0018	0.00243	CcSEcCtD
Sitaxentan—Somnolence—Hydroxyurea—head and neck cancer	0.00179	0.00243	CcSEcCtD
Sitaxentan—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.00178	0.00684	CbGpPWpGaD
Sitaxentan—Dyspepsia—Hydroxyurea—head and neck cancer	0.00178	0.0024	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—KISS1—head and neck cancer	0.00176	0.00673	CbGpPWpGaD
Sitaxentan—Decreased appetite—Hydroxyurea—head and neck cancer	0.00176	0.00237	CcSEcCtD
Sitaxentan—Pancytopenia—Docetaxel—head and neck cancer	0.00175	0.00237	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00174	0.00236	CcSEcCtD
Sitaxentan—Fatigue—Hydroxyurea—head and neck cancer	0.00174	0.00235	CcSEcCtD
Sitaxentan—Pain—Hydroxyurea—head and neck cancer	0.00173	0.00234	CcSEcCtD
Sitaxentan—Constipation—Hydroxyurea—head and neck cancer	0.00173	0.00234	CcSEcCtD
Sitaxentan—Weight decreased—Docetaxel—head and neck cancer	0.00167	0.00226	CcSEcCtD
Sitaxentan—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00166	0.00225	CcSEcCtD
Sitaxentan—Anaemia—Fluorouracil—head and neck cancer	0.00165	0.00223	CcSEcCtD
Sitaxentan—Infestation—Docetaxel—head and neck cancer	0.00164	0.00222	CcSEcCtD
Sitaxentan—Infestation NOS—Docetaxel—head and neck cancer	0.00164	0.00222	CcSEcCtD
Sitaxentan—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.00164	0.00629	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Vinblastine—head and neck cancer	0.00163	0.00221	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00162	0.00219	CcSEcCtD
Sitaxentan—Renal failure—Docetaxel—head and neck cancer	0.00162	0.00219	CcSEcCtD
Sitaxentan—Myocardial infarction—Docetaxel—head and neck cancer	0.00161	0.00218	CcSEcCtD
Sitaxentan—Jaundice—Docetaxel—head and neck cancer	0.0016	0.00217	CcSEcCtD
Sitaxentan—Stomatitis—Docetaxel—head and neck cancer	0.0016	0.00217	CcSEcCtD
Sitaxentan—Conjunctivitis—Docetaxel—head and neck cancer	0.0016	0.00216	CcSEcCtD
Sitaxentan—Body temperature increased—Hydroxyurea—head and neck cancer	0.0016	0.00216	CcSEcCtD
Sitaxentan—Leukopenia—Fluorouracil—head and neck cancer	0.00159	0.00216	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—GRP—head and neck cancer	0.00159	0.00611	CbGpPWpGaD
Sitaxentan—Asthenia—Vinblastine—head and neck cancer	0.00159	0.00215	CcSEcCtD
Sitaxentan—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.00158	0.00605	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—HRAS—head and neck cancer	0.00156	0.00599	CbGpPWpGaD
Sitaxentan—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00156	0.0021	CcSEcCtD
Sitaxentan—Epistaxis—Docetaxel—head and neck cancer	0.00155	0.0021	CcSEcCtD
Sitaxentan—Chest pain—Fluorouracil—head and neck cancer	0.00152	0.00205	CcSEcCtD
Sitaxentan—Diarrhoea—Vinblastine—head and neck cancer	0.00151	0.00205	CcSEcCtD
Sitaxentan—Discomfort—Fluorouracil—head and neck cancer	0.0015	0.00203	CcSEcCtD
Sitaxentan—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00149	0.00201	CcSEcCtD
Sitaxentan—Haemoglobin—Docetaxel—head and neck cancer	0.00148	0.00201	CcSEcCtD
Sitaxentan—Rhinitis—Docetaxel—head and neck cancer	0.00148	0.002	CcSEcCtD
Sitaxentan—Haemorrhage—Docetaxel—head and neck cancer	0.00148	0.002	CcSEcCtD
Sitaxentan—Hepatitis—Docetaxel—head and neck cancer	0.00148	0.002	CcSEcCtD
Sitaxentan—Confusional state—Fluorouracil—head and neck cancer	0.00147	0.00198	CcSEcCtD
Sitaxentan—Dizziness—Vinblastine—head and neck cancer	0.00146	0.00198	CcSEcCtD
Sitaxentan—Urinary tract disorder—Docetaxel—head and neck cancer	0.00146	0.00197	CcSEcCtD
Sitaxentan—Oedema peripheral—Docetaxel—head and neck cancer	0.00145	0.00197	CcSEcCtD
Sitaxentan—Oedema—Fluorouracil—head and neck cancer	0.00145	0.00197	CcSEcCtD
Sitaxentan—Asthenia—Hydroxyurea—head and neck cancer	0.00145	0.00196	CcSEcCtD
Sitaxentan—Urethral disorder—Docetaxel—head and neck cancer	0.00145	0.00196	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—GRP—head and neck cancer	0.00145	0.00554	CbGpPWpGaD
Sitaxentan—Infection—Fluorouracil—head and neck cancer	0.00144	0.00195	CcSEcCtD
Sitaxentan—Nervous system disorder—Fluorouracil—head and neck cancer	0.00143	0.00193	CcSEcCtD
Sitaxentan—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00142	0.00192	CcSEcCtD
Sitaxentan—Visual impairment—Docetaxel—head and neck cancer	0.00142	0.00192	CcSEcCtD
Sitaxentan—Tachycardia—Fluorouracil—head and neck cancer	0.00142	0.00192	CcSEcCtD
Sitaxentan—Vomiting—Vinblastine—head and neck cancer	0.00141	0.0019	CcSEcCtD
Sitaxentan—Headache—Vinblastine—head and neck cancer	0.00139	0.00188	CcSEcCtD
Sitaxentan—Anorexia—Fluorouracil—head and neck cancer	0.00139	0.00187	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—KISS1—head and neck cancer	0.00138	0.00531	CbGpPWpGaD
Sitaxentan—Diarrhoea—Hydroxyurea—head and neck cancer	0.00138	0.00187	CcSEcCtD
Sitaxentan—Eye disorder—Docetaxel—head and neck cancer	0.00138	0.00187	CcSEcCtD
Sitaxentan—EDNRA—Endothelins—AKT1—head and neck cancer	0.00138	0.00529	CbGpPWpGaD
Sitaxentan—Cardiac disorder—Docetaxel—head and neck cancer	0.00137	0.00185	CcSEcCtD
Sitaxentan—Flushing—Docetaxel—head and neck cancer	0.00137	0.00185	CcSEcCtD
Sitaxentan—Hypotension—Fluorouracil—head and neck cancer	0.00136	0.00184	CcSEcCtD
Sitaxentan—Angiopathy—Docetaxel—head and neck cancer	0.00134	0.00181	CcSEcCtD
Sitaxentan—Dizziness—Hydroxyurea—head and neck cancer	0.00134	0.00181	CcSEcCtD
Sitaxentan—Immune system disorder—Docetaxel—head and neck cancer	0.00133	0.0018	CcSEcCtD
Sitaxentan—Mediastinal disorder—Docetaxel—head and neck cancer	0.00133	0.0018	CcSEcCtD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—GPX1—head and neck cancer	0.00132	0.00508	CbGpPWpGaD
Sitaxentan—Nausea—Vinblastine—head and neck cancer	0.00132	0.00178	CcSEcCtD
Sitaxentan—Insomnia—Fluorouracil—head and neck cancer	0.00131	0.00178	CcSEcCtD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.00131	0.00502	CbGpPWpGaD
Sitaxentan—Alopecia—Docetaxel—head and neck cancer	0.0013	0.00176	CcSEcCtD
Sitaxentan—Mental disorder—Docetaxel—head and neck cancer	0.00129	0.00175	CcSEcCtD
Sitaxentan—Somnolence—Fluorouracil—head and neck cancer	0.00129	0.00175	CcSEcCtD
Sitaxentan—Malnutrition—Docetaxel—head and neck cancer	0.00129	0.00174	CcSEcCtD
Sitaxentan—Vomiting—Hydroxyurea—head and neck cancer	0.00128	0.00174	CcSEcCtD
Sitaxentan—Dyspepsia—Fluorouracil—head and neck cancer	0.00128	0.00173	CcSEcCtD
Sitaxentan—Rash—Hydroxyurea—head and neck cancer	0.00127	0.00172	CcSEcCtD
Sitaxentan—Dermatitis—Hydroxyurea—head and neck cancer	0.00127	0.00172	CcSEcCtD
Sitaxentan—Headache—Hydroxyurea—head and neck cancer	0.00126	0.00171	CcSEcCtD
Sitaxentan—Decreased appetite—Fluorouracil—head and neck cancer	0.00126	0.00171	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—KISS1—head and neck cancer	0.00126	0.00482	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00125	0.0017	CcSEcCtD
Sitaxentan—Pain—Fluorouracil—head and neck cancer	0.00124	0.00168	CcSEcCtD
Sitaxentan—Muscle spasms—Docetaxel—head and neck cancer	0.00124	0.00167	CcSEcCtD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	0.00121	0.00463	CbGpPWpGaD
Sitaxentan—Nausea—Hydroxyurea—head and neck cancer	0.0012	0.00162	CcSEcCtD
Sitaxentan—Feeling abnormal—Fluorouracil—head and neck cancer	0.0012	0.00162	CcSEcCtD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.00119	0.00458	CbGpPWpGaD
Sitaxentan—Anaemia—Docetaxel—head and neck cancer	0.00119	0.00161	CcSEcCtD
Sitaxentan—Urticaria—Fluorouracil—head and neck cancer	0.00115	0.00156	CcSEcCtD
Sitaxentan—Leukopenia—Docetaxel—head and neck cancer	0.00115	0.00156	CcSEcCtD
Sitaxentan—Body temperature increased—Fluorouracil—head and neck cancer	0.00115	0.00155	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—GRP—head and neck cancer	0.00114	0.00437	CbGpPWpGaD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.00113	0.00434	CbGpPWpGaD
Sitaxentan—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00112	0.00429	CbGpPWpGaD
Sitaxentan—Chest pain—Docetaxel—head and neck cancer	0.00109	0.00148	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00109	0.00147	CcSEcCtD
Sitaxentan—Hypersensitivity—Fluorouracil—head and neck cancer	0.00107	0.00145	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	0.00107	0.0041	CbGpPWpGaD
Sitaxentan—Dry mouth—Docetaxel—head and neck cancer	0.00107	0.00145	CcSEcCtD
Sitaxentan—Confusional state—Docetaxel—head and neck cancer	0.00106	0.00143	CcSEcCtD
Sitaxentan—Oedema—Docetaxel—head and neck cancer	0.00105	0.00142	CcSEcCtD
Sitaxentan—Infection—Docetaxel—head and neck cancer	0.00104	0.00141	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—NAT2—head and neck cancer	0.00104	0.00399	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KISS1—head and neck cancer	0.00104	0.00398	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—GRP—head and neck cancer	0.00103	0.00397	CbGpPWpGaD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.00103	0.00396	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Docetaxel—head and neck cancer	0.00103	0.00139	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—NAT2—head and neck cancer	0.00103	0.00394	CbGpPWpGaD
Sitaxentan—Thrombocytopenia—Docetaxel—head and neck cancer	0.00103	0.00139	CcSEcCtD
Sitaxentan—Tachycardia—Docetaxel—head and neck cancer	0.00102	0.00138	CcSEcCtD
Sitaxentan—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00102	0.00391	CbGpPWpGaD
Sitaxentan—Skin disorder—Docetaxel—head and neck cancer	0.00102	0.00138	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	0.00102	0.00391	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	0.00102	0.00391	CbGpPWpGaD
Sitaxentan—Anorexia—Docetaxel—head and neck cancer	0.001	0.00135	CcSEcCtD
Sitaxentan—Diarrhoea—Fluorouracil—head and neck cancer	0.000994	0.00135	CcSEcCtD
Sitaxentan—EDNRB—G alpha (q) signalling events—PIK3CA—head and neck cancer	0.000988	0.00379	CbGpPWpGaD
Sitaxentan—Hypotension—Docetaxel—head and neck cancer	0.00098	0.00133	CcSEcCtD
Sitaxentan—Dizziness—Fluorouracil—head and neck cancer	0.000961	0.0013	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—NAT2—head and neck cancer	0.00095	0.00364	CbGpPWpGaD
Sitaxentan—Insomnia—Docetaxel—head and neck cancer	0.000949	0.00128	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	0.000937	0.00359	CbGpPWpGaD
Sitaxentan—Somnolence—Docetaxel—head and neck cancer	0.000933	0.00126	CcSEcCtD
Sitaxentan—Vomiting—Fluorouracil—head and neck cancer	0.000924	0.00125	CcSEcCtD
Sitaxentan—Dyspepsia—Docetaxel—head and neck cancer	0.000923	0.00125	CcSEcCtD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000918	0.00352	CbGpPWpGaD
Sitaxentan—Rash—Fluorouracil—head and neck cancer	0.000916	0.00124	CcSEcCtD
Sitaxentan—Dermatitis—Fluorouracil—head and neck cancer	0.000916	0.00124	CcSEcCtD
Sitaxentan—Decreased appetite—Docetaxel—head and neck cancer	0.000912	0.00123	CcSEcCtD
Sitaxentan—Headache—Fluorouracil—head and neck cancer	0.00091	0.00123	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000906	0.00123	CcSEcCtD
Sitaxentan—Fatigue—Docetaxel—head and neck cancer	0.000904	0.00122	CcSEcCtD
Sitaxentan—Pain—Docetaxel—head and neck cancer	0.000897	0.00121	CcSEcCtD
Sitaxentan—Constipation—Docetaxel—head and neck cancer	0.000897	0.00121	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.000884	0.00339	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Docetaxel—head and neck cancer	0.000864	0.00117	CcSEcCtD
Sitaxentan—Nausea—Fluorouracil—head and neck cancer	0.000863	0.00117	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—GRP—head and neck cancer	0.000854	0.00328	CbGpPWpGaD
Sitaxentan—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000842	0.00323	CbGpPWpGaD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000837	0.00321	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—STAT6—head and neck cancer	0.000829	0.00318	CbGpPWpGaD
Sitaxentan—Body temperature increased—Docetaxel—head and neck cancer	0.000829	0.00112	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.000818	0.00314	CbGpPWpGaD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000779	0.00299	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Docetaxel—head and neck cancer	0.000773	0.00105	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	0.000766	0.00294	CbGpPWpGaD
Sitaxentan—Asthenia—Docetaxel—head and neck cancer	0.000753	0.00102	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—KISS1—head and neck cancer	0.000742	0.00285	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—YAP1—head and neck cancer	0.000734	0.00281	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	0.000729	0.0028	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	0.000729	0.00279	CbGpPWpGaD
Sitaxentan—Diarrhoea—Docetaxel—head and neck cancer	0.000718	0.000971	CcSEcCtD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000711	0.00272	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—PIK3CA—head and neck cancer	0.000707	0.00271	CbGpPWpGaD
Sitaxentan—Dizziness—Docetaxel—head and neck cancer	0.000694	0.000938	CcSEcCtD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000681	0.00261	CbGpPWpGaD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000672	0.00258	CbGpPWpGaD
Sitaxentan—Vomiting—Docetaxel—head and neck cancer	0.000667	0.000902	CcSEcCtD
Sitaxentan—Rash—Docetaxel—head and neck cancer	0.000661	0.000895	CcSEcCtD
Sitaxentan—Dermatitis—Docetaxel—head and neck cancer	0.000661	0.000894	CcSEcCtD
Sitaxentan—Headache—Docetaxel—head and neck cancer	0.000657	0.000889	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.000633	0.00243	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.000626	0.0024	CbGpPWpGaD
Sitaxentan—Nausea—Docetaxel—head and neck cancer	0.000623	0.000843	CcSEcCtD
Sitaxentan—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.000618	0.00237	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GRP—head and neck cancer	0.000611	0.00234	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STAT6—head and neck cancer	0.000594	0.00228	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.000585	0.00224	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000552	0.00212	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—YAP1—head and neck cancer	0.000525	0.00201	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—GSTM1—head and neck cancer	0.000514	0.00197	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSTM1—head and neck cancer	0.000507	0.00195	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—CYP1A1—head and neck cancer	0.000488	0.00187	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000481	0.00184	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	0.000469	0.0018	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	0.000463	0.00177	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	0.000445	0.00171	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000439	0.00168	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—UROD—head and neck cancer	0.000429	0.00164	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—IL2—head and neck cancer	0.000424	0.00163	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—UROD—head and neck cancer	0.000391	0.0015	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL2—head and neck cancer	0.000385	0.00148	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000333	0.00128	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NOTCH1—head and neck cancer	0.000331	0.00127	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—MAPK3—head and neck cancer	0.00031	0.00119	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	0.000309	0.00119	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	0.000305	0.00117	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—IL2—head and neck cancer	0.000304	0.00116	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000303	0.00116	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—MAPK1—head and neck cancer	0.000295	0.00113	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—EGFR—head and neck cancer	0.000295	0.00113	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	0.000293	0.00112	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000289	0.00111	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000282	0.00108	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL2—head and neck cancer	0.000276	0.00106	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—UROD—head and neck cancer	0.000258	0.000989	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CA—head and neck cancer	0.000256	0.000981	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NOTCH1—head and neck cancer	0.000237	0.000908	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HRAS—head and neck cancer	0.000237	0.000907	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AKT1—head and neck cancer	0.00023	0.000882	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL2—head and neck cancer	0.000228	0.000873	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCND1—head and neck cancer	0.000222	0.000851	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—MAPK3—head and neck cancer	0.000222	0.00085	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTEN—head and neck cancer	0.000214	0.000821	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—MAPK1—head and neck cancer	0.000211	0.000809	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—EGFR—head and neck cancer	0.000211	0.000809	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AKT1—head and neck cancer	0.000209	0.000801	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000202	0.000773	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VEGFA—head and neck cancer	0.000193	0.000742	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—STAT3—head and neck cancer	0.000192	0.000734	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000189	0.000725	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000187	0.000718	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CA—head and neck cancer	0.000183	0.000702	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK3—head and neck cancer	0.000183	0.000702	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NAT2—head and neck cancer	0.000178	0.000683	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK1—head and neck cancer	0.000174	0.000668	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGFR—head and neck cancer	0.000174	0.000668	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000172	0.000661	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000171	0.000655	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HRAS—head and neck cancer	0.000169	0.000649	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AKT1—head and neck cancer	0.000165	0.000631	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2—head and neck cancer	0.000163	0.000625	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NAT2—head and neck cancer	0.000162	0.000623	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCND1—head and neck cancer	0.000159	0.000609	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—DPYD—head and neck cancer	0.000156	0.000599	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTEN—head and neck cancer	0.000153	0.000588	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CA—head and neck cancer	0.000151	0.000579	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AKT1—head and neck cancer	0.00015	0.000573	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—YAP1—head and neck cancer	0.000148	0.000568	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—head and neck cancer	0.000146	0.00056	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—DPYD—head and neck cancer	0.000142	0.000546	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HRAS—head and neck cancer	0.00014	0.000536	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VEGFA—head and neck cancer	0.000138	0.000531	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STAT3—head and neck cancer	0.000137	0.000526	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—YAP1—head and neck cancer	0.000135	0.000518	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK3—head and neck cancer	0.000131	0.000502	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK1—head and neck cancer	0.000125	0.000478	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGFR—head and neck cancer	0.000125	0.000478	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AKT1—head and neck cancer	0.000123	0.000473	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000111	0.000427	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CA—head and neck cancer	0.000108	0.000415	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NAT2—head and neck cancer	0.000107	0.000411	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—head and neck cancer	0.000105	0.000401	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000102	0.000389	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HRAS—head and neck cancer	0.0001	0.000384	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	9.71e-05	0.000372	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—DPYD—head and neck cancer	9.39e-05	0.00036	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—YAP1—head and neck cancer	8.91e-05	0.000342	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TYMS—head and neck cancer	8.9e-05	0.000341	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	8.86e-05	0.00034	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AKT1—head and neck cancer	8.83e-05	0.000339	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTM1—head and neck cancer	8.8e-05	0.000337	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GPX1—head and neck cancer	8.43e-05	0.000323	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP1A1—head and neck cancer	8.34e-05	0.00032	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TYMS—head and neck cancer	8.12e-05	0.000311	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTM1—head and neck cancer	8.02e-05	0.000308	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GPX1—head and neck cancer	7.68e-05	0.000295	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP1A1—head and neck cancer	7.6e-05	0.000292	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	6.85e-05	0.000263	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	6.25e-05	0.00024	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TYMS—head and neck cancer	5.35e-05	0.000205	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTM1—head and neck cancer	5.29e-05	0.000203	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GPX1—head and neck cancer	5.07e-05	0.000194	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP1A1—head and neck cancer	5.02e-05	0.000192	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—head and neck cancer	4.96e-05	0.00019	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—head and neck cancer	4.52e-05	0.000173	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTEN—head and neck cancer	4.33e-05	0.000166	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTEN—head and neck cancer	3.94e-05	0.000151	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CA—head and neck cancer	3.05e-05	0.000117	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—head and neck cancer	2.98e-05	0.000114	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CA—head and neck cancer	2.78e-05	0.000107	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTEN—head and neck cancer	2.6e-05	9.97e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AKT1—head and neck cancer	2.49e-05	9.56e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AKT1—head and neck cancer	2.27e-05	8.72e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.83e-05	7.04e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AKT1—head and neck cancer	1.5e-05	5.75e-05	CbGpPWpGaD
